CATALYST PHARMACEUTICALS INC
CATALYST PHARMACEUTICALS INC logo
CPRX

CATALYST PHARMACEUTICALS INC (CPRX)

$17.273.85%

Market is closed
– opens on 8 PM, 05 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$16.645
Day's Range
$17.5279
$5.24
52-Week Range
$18.39
1 month return22.83%
3 month return25.42%
1 year return149.21%
5 year return298.85%

Company Information

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia gravis (MuSK-MG) and other neurological and neuromuscular disorders. Catalyst's New Drug Application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was approved in 2018 by the U.S. Food & Drug Administration ('FDA'), and Firdapse is now commercially available in the United States. Further, Canada's national healthcare regulatory agency, Health Canada, recently approved the use of Firdapse® (amifampridine) for the treatment of patients in Canada with LEMS.
OrganizationCATALYST PHARMACEUTICALS INC
Employees76
CEOMr. Patrick J. McEnany
IndustryHealth Technology

Analyst Recommendation

based on 5 analysts ratings

Buy
100%
Buy
0%
Hold
0%
Sell

Based on 5 Wall street analysts offering stock ratings for CATALYST PHARMACEUTICALS INC(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 4.81%

Current

$17.27

Target

$18.1

Recommendation Trend

Based on 5 analyst

Current1M Ago3M Ago
Buy
5
9
10
Hold
0
2
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
1.7B
Book Value
$2.6
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
0.6
PE Ratio
27.72
PEG Ratio
0.0
Wall Street Target Price
18.1

Valuation

Trailing PE27.72
Forward PE19.49
Price/Book (mrq)
6.54
Enterprise Value
1.5B
Enterprise Value/Revenue
7.9
Enterprise Value/Ebitda
17.93

Technicals

Beta
1.27
50 Day MA
13.99
200 Day MA
10.32

Institutional Holdings

State Street Corporation

7.26%

Vanguard Group Inc

5.9%

Deerfield Management Co

4.7%

LSV Asset Management

3.26%

Millennium Management LLC

2.62%

Dimensional Fund Advisors, Inc.

2.06%

Discover more

Frequently Asked Questions

What is CATALYST PHARMACEUTICALS INC share price today?

Can Indians buy CATALYST PHARMACEUTICALS INC shares?

How can I buy CATALYST PHARMACEUTICALS INC shares from India?

Can Fractional shares of CATALYST PHARMACEUTICALS INC be purchased?

What are the documents required to start investing in CATALYST PHARMACEUTICALS INC stocks?

What are today’s High and Low prices of CATALYST PHARMACEUTICALS INC?

What are today’s traded volumes of CATALYST PHARMACEUTICALS INC?

What is today’s market capitalisation of CATALYST PHARMACEUTICALS INC?

What is the 52 Week High and Low Range of CATALYST PHARMACEUTICALS INC?

How much percentage CATALYST PHARMACEUTICALS INC is down from its 52 Week High?

How much percentage CATALYST PHARMACEUTICALS INC is up from its 52 Week low?

What are the historical returns of CATALYST PHARMACEUTICALS INC?

Who is the Chief Executive Officer (CEO) of CATALYST PHARMACEUTICALS INC?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*